NASDAQ : ETRA
Electra Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 508.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 508.41M |
| Enterprise Value | 412.67M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 22, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 62.77M |
| Shares Outstanding | 62.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.37% |
| Owned by Institutions (%) | 1.29% |
| Float | 29.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.37 |
| Quick Ratio | 7.19 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -78.44 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -93.41% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.07M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 28.89 |
| Average Volume (20 Days) | 348,500 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 409,380 |
| Short Previous Month | 702,266 |
| Short % of Shares Out | 0.65% |
| Short % of Float | 1.37% |
| Short Ratio (days to cover) | 0.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -86.75M |
| Pretax Income | -85.53M |
| Net Income | -95.20M |
| EBITDA | n/a |
| EBIT | -86.75M |
| Earnings Per Share (EPS) | -$2,163.66 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 97.73M |
| Total Debt | 1.98M |
| Net Cash | 95.74M |
| Net Cash Per Share | $1.53 |
| Equity (Book Value) | 91.72M |
| Book Value Per Share | -4,987.61 |
| Working Capital | 86.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -74.68M |
| Capital Expenditures | -644,000 |
| Depreciation & Amortization | 183,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -75.32M |
| FCF Per Share | -$1.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -26,711.84% |
| FCF Yield | -14.81% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.20 |
| Price Target Difference | 309.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |